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Background: Introduction of calcineurin inhibitors had led to improved survival rates in liver transplant recipients.
However, long-term use of calcineurin inhibitors is associated with a higher risk of chronic renal failure, neurotoxicity,
de novo malignancies, recurrence of hepatitis C viral (HCV) infection and hepatocellular carcinoma. Several studies have
shown that everolimus has the potential to provide protection against viral replication, malignancy, and progression of
fibrosis, as well as preventing nephrotoxicity by facilitating calcineurin inhibitor reduction without compromising efficacy.
The Hephaistos study evaluates the beneficial effects of early initiation of everolimus in de novo liver transplant recipients.
Methods/Design: Hephaistos is an ongoing 12-month, multi-center, open-label, controlled study aiming to enroll 330
de novo liver transplant recipients from 15 centers across Germany. Patients are randomized in a 1:1 ratio (7–21 days
post-transplantation) to receive everolimus (trough levels 3–8 ng/mL) with reduced tacrolimus (trough levels <5 ng/mL),
or standard tacrolimus (trough levels 6–10 ng/mL) after entering a run-in period (3–5 days post-transplantation). In the
run-in period, patients are treated with induction therapy, mycophenolate mofetil, tacrolimus, and corticosteroids
according to local practice. Randomization is stratified by HCV status and model of end-stage liver disease scores at
transplantation. The primary objective of the study is to exhibit superior renal function (estimated glomerular filtration rate
assessed by the Modification of Diet in Renal Disease (MDRD)-4 formula) with everolimus plus reduced tacrolimus
compared to standard tacrolimus at Month 12. Other objectives are: to assess the incidence of treated biopsy-proven
acute rejection, graft loss, or death; the incidences of components of the composite efficacy endpoint; renal function via
estimated glomerular filtration rate using various formulae (MDRD-4, Nankivell, Cockcroft-Gault, chronic kidney disease
epidemiology collaboration and Hoek formulae); the incidence of proteinuria; the incidence of adverse events and serious
adverse events; the incidence and severity of cytomegalovirus and HCV infections and HCV-related fibrosis.
Discussion: This study aims to demonstrate superior renal function, comparable efficacy, and safety in de novo liver
transplant recipients receiving everolimus with reduced tacrolimus compared with standard tacrolimus. This study also
evaluates the antiviral benefit by early initiation of everolimus.
Trial registration: NCT01551212.
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Liver transplantation: challenges for long-term outcomes
Liver transplantation is the most preferred and well-
established mode of treatment in patients with end-stage
liver diseases. From 1968 to 2009, approximately 93,634 liver
transplantations were carried out in 83,816 patients in
Europe. Of these, 14,116 liver transplantations were per-
formed in Germany [1] from across 24 centers [2]. Around
1,097 liver transplantations were performed in 2012 and the
1-year patient survival rate is 76.6% (733 of the 957 patients
with known survival status) [3]. Analysis of data across cen-
ters in Germany (2007 to 2010) reveals that better 1-year
overall survival rates were significantly correlated with larger
center size (R2 = 0.09, P= 0.009), whereas in-house mortality
(R2 = 0.007, P= 0.52) and 3-year survival rates (R2 = 0.05,
P= 0.09) showed non-significant correlation between center
volume and outcome [4]. Model of end-stage liver disease
(MELD) score was introduced in Germany in 2006 for thor-
ough and transparent liver allograft allocation. Following the
introduction of MELD, mortality on the waiting list de-
creased; however, 1-year survival rates also decreased from
90% to less than 80% [5,6]. The match MELD threshold in-
creased from 25 to 34 [6,7]. A vast number (~40%) of pa-
tients are transplanted with a MELD score >30 [6,8].
Greater surgical expertise, better selection of patients, im-
proved post-liver transplantation management of complica-
tions [1], and introduction of potent immunosuppressants,
antibiotics and antiviral drugs are the key reasons for im-
provement in the survival rates [9]. Calcineurin inhibitors
(CNIs) are the mainstay of immunosuppressive therapy in
liver transplantation. However, post-transplant long-term
use of CNIs is associated with a higher risk of chronic renal
failure in liver transplant recipients [10,11] and in renal
transplantation recipients [12]. Among the liver transplant
recipients, approximately 20% of patients develop chronic
renal failure (glomerular filtration rate of 29 mL/min/
1.73 m2) by 5 years [10], leading to increased mortality
[13,14]. Prolonged CNI exposure is also associated with
neurotoxicity, de novo malignancies, recurrence of hepa-
titis C viral (HCV) infection and hepatocellular carcinoma
(HCC) [15], and an increased risk of metabolic complica-
tions [11]. Therefore, it is important to identify alternate
immunosuppressive regimens that: (1) maintain efficacy
similar to CNI and optimize renal function while reducing
CNI exposure and thus related nephrotoxicity; (2)
minimize CNI-associated adverse events; and (3) reduce
the post-transplant recurrence of HCV and HCC and
occurrence of de novo malignancies [15].
Eliminating/reducing calcineurin inhibitor exposure:
mammalian target of rapamycin inhibitors
Mammalian target of rapamycin (mTOR) inhibitor (evero-
limus, sirolimus)-based CNI reduction or elimination is be-
ing practiced to overcome drug-induced adverse events.mTOR inhibitor-enabled reduced CNI exposure offers
renal benefits without affecting efficacy in low-to-moderate
risk de novo kidney transplant recipients [12]. Emerging
data suggest that mTOR inhibitors offer antiviral benefits
against BK virus, human papilloma virus, cytomegalovirus
(CMV), human herpes virus 8 and several other herpes vi-
ruses [16]. Early initiation of mTOR inhibitor-based im-
munosuppression is more effective in reducing the risk of
CMV infection and disease in solid organ transplant recipi-
ents [17]. Furthermore, a probable negative impact of
mTOR inhibitors in post-operative surgical complications
[15,18] was contradicted by findings from a single-center
study in six liver transplant recipients, indicating that the
rate of complications after major surgery is similar in pa-
tients receiving mTOR inhibitors to those not receiving
mTOR inhibitors [19].
Everolimus in liver transplantation
Studies in de novo and maintenance liver transplant recipi-
ents demonstrated that everolimus facilitates CNI reduc-
tion/elimination without compromising efficacy (Table 1).
Using an appropriate dose and switching to everolimus
within 3 months of transplantation optimizes renal func-
tion and minimizes CNI-induced adverse events with com-
parable efficacy [20-32]. Other potential benefits of mTOR
inhibitors related to HCV-related fibrosis, metabolic syn-
drome, and neurotoxicity have long-term implications for
liver transplant recipients [15].
H2304, the registry study for everolimus use in liver
transplantation, reported beneficial effects of everolimus
[25]. Results from the H2304 study suggested that, despite
the beneficial effects of everolimus initiation 30 ± 5 days
post-transplantation, incidences of CMV and HCC recur-
rence were comparable (CMV: 4.9% versus 5.4%, P = 0.84;
and HCC recurrence: 1.2% versus 1.2%, P = 1.0) between
the everolimus plus reduced tacrolimus and the standard
tacrolimus arms, respectively, at 24 months [25].
Initiation of everolimus earlier than 30 ± 5 days post-
transplantation might provide antiviral benefits. There-
fore, the Hephaistos study (NCT01551212; Efficacy of
Everolimus in Combination With Tacrolimus in Liver
Transplant Recipients) aims to establish the beneficial
effects of early initiation of everolimus and the impact
on the development or the rate of progression of fibrosis
in HCV-positive recipients without affecting wound
healing. A very low initial immunosuppressant dosage
has been used, considering the relevant number of pa-
tients in Germany with a MELD score >30, who are in a
poor health condition at the time of transplantation.
Methods/Design: Hephaistos study
Overview
Hephaistos (protocol version 3, 14 June 2013) is an on-
going, 12-month, multicenter, open-label, randomized,
Table 1 Everolimus in liver transplantation
Study Participants Study design
and duration
EVR dosing Efficacy Renal function Safety
Early conversion (≤3 months after transplantation)
Levy et al.
[20]
N = 119 recipients Prospective,
randomized;
36 months
1, 2, or 4 mg/day 32.1, 26.7, and 25.8 for EVR 1, 2,
and 4 mg/day at 1 year after
immunosuppression was initiated;
39.3, 30.0, and 29.0 for EVR 1, 2,
and 4 mg/day at 3 years after
immunosuppression was initiated
Change in CrCl (mL/min) from
baseline at 1 year post-conversion:
EVR 1, 2, and 4 mg/day vs
placebo: −20.2, −43.0,
and −36.9 vs −36.9
• CMV disease: 3.3, 3.6, 6.7, and
9.7 (placebo vs EVR 1, 2,
and 4 mg/day, respectively, P = NS
for all comparisons)
• n = 28 (EVR
1.0 mg) + CNI
• n = 30 (EVR
2.0 mg) + CNI
• n =31 (EVR
4.0 mg) + CNI
• n =30 (placebo)
+ CNI
• Thrombocytopenia: 10.0, 14.3,
20.0, and 19.4
• Leukopenia: 0, 14.3, 6.7, and
6.5
Masetti et al.
[21]
N = 78 recipients Prospective,
randomized;
12 months
Initial dose: 2.0 mg/day,
C0→ 6–10 ng/mL post-
CsA withdrawal:
C0→ 8–12 ng/mL until
Month 6, and C0→ 6–10 ng/mL
thereafter
5.7 vs 7.7 at 40–87 days vs at
41–240 days after transplant (NS)
Change in GFR (mL/min/1.73 m2)
1 year after conversion: EVR
vs CsA: +5.9 vs −14.8 (P < 0.001)
EVR vs CsA
• Inferior limb edema: 9.6 vs 0• n = 52 (EVR)
• n = 26 (CsA) • Incisional hernia: 46.1 vs 26.9
• Biliary complications
(stenosis/leak): 21.1 vs 30.8
• Infections: 46.1 vs 46.1
• CMV: 19.2 vs 23.1
(P = NS for all comparisons)
Fischer et al.
[22]
N = 203 recipients
on CNI without
corticosteroids
Prospective,
randomized;
12 months
Initial dose of 1.5 mg b.i.d.;
target C0→ 5–12 ng/mL in
patients on treatment with
TAC; C0→ 8–12 ng/mL in
patients on treatment with CsA
EVR vs CNI control at 11
months: 17.7 vs 15.3
EVR vs CNI: change in
GFR (mL/min/1.73 m2)
11 months after conversion
from baseline (MDRD): 2.0 ± 23.2
vs −2.8 ± 23.1; LS mean
difference ± SE: −7.778 ± 3.338
(P = 0.021)a
EVR vs CNI
• Wound complications: 2 vs 3.9
• n = 101 (EVR) • Incisional hernia: 11.9 vs 9.8
• n = 102 (CNI
continuation)
• Wound dehiscence: 0 vs 1
• Wound hemorrhage: 1 vs 0
• Infections and
infestations: 73.3 vs 59.8
• Anemia: 18.8 vs 10.8
• Leukopenia: 20.8 vs 9.8b
• Thrombocytopenia: 7.9 vs 6.9
(P = NS for anemia and
thrombocytopenia)
Sterneck et al.
[23]
N = 81 recipients
from Fischer et al.
[22]
Prospective,
randomized;
35 months
Same as Fischer et al. [22] EVR vs CNI control at
35 months: 24.4 vs 15.8 (P = NS)
Change in GFR 35 months after
conversion: difference in eGFR
between EVR and CNI
(CG): −10.5 mL/min (P = 0.096)
EVR vs CNI
• Peripheral edema: 22.0 vs
5.0 (P = 0.048)
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Table 1 Everolimus in liver transplantation (Continued)
and Nankivell
formula: −10.5 mL/min (P = 0.015)
• Neoplasms:17.1 vs 19.8
(P = 0.587)
• n = 41 (EVR ±
corticosteroids)
• n = 40 (CNI ±
corticosteroids)
• Incisional hernia: 24.4 vs
15.0 (P = 0.404)
• Anemia: 4.9 vs 5.0 (P = 1.000)
De Simone et
al. [24]
N = 719 recipients Prospective,
randomized;
12 months
EVR + TAC-WD: initial dose
of 1.0 mg b.i.d. ≤24 hours
of randomization and
C0 3–8 ng/mL until
Month 4 post-Tx. Target C0
increased to 6–10 ng/mL.
EVR + rTAC: initial dose
of 1.0 mg b.i.d. ≤24 hours of
randomization and C0 3–8 ng/mL
maintained throughout the study.
Recruitment to EVR + TAC-WD
arm was terminated early.
EVR + rTAC vs TAC-C:
4.1 vs 10.7, P = 0.005
Change in GFR (mL/min/1.73 m2)
1 year after conversion: adjusted
mean difference in eGFR change
for EVR + rTAC vs TAC-C: 8.50 ±
2.12; P < 0.001)
EVR + rTAC vs TAC-C:
• n = 245 (EVR +
rTAC)
• Edema: 17.6 vs 10.8 (RR 1.63;
95% CI: 1.03, 2.56)
• n = 231 (EVR +
TAC-WD)
• Wound complications: 11.0 vs
7.9 (RR 1.40; 95% CI: 0.80, 2.45)
• n = 243 (TAC-C) • Incisional hernia: 2.9 vs 1.2
(RR 2.30, 95% CI: 0.60, 8.77)
• Leukopenia: 11.8 vs 5.0
(RR 2.38, 95% CI: 1.24, 4.55)
• Thrombocytopenia: 5.3 vs 1.7
• Anemia: 7.8 vs 8.3 (RR 0.93, 95%
CI: 0.51, 1.71)
Saliba et al.
[25]
Same as De
Simone et al. [24]
Prospective,
randomized;
24 months
Same as De Simone et al. [24] 6.1 vs 13.3; −7.2% (97.5% CI:
−13.5, −0.9; P = 0.010). EVR +
rTAC vs TAC-C at 24 months)
Change in GFR (mL/min/1.73 m2)
24 months after conversion:
EVR + rTAC vs TAC-C: mean
difference in eGFR change:
+6.7 (97.5% CI: +1.9, +11.4;
P = 0.002)
EVR + rTAC vs TAC-C:
• Peripheral edema: 22.4 vs
14.9 (P = 0.036)
• Wound complications: 11.0 vs
8.3 (P = 0.36)
• Incisional hernia: 9.8 vs
7.9 (P = 0.52)
• Thrombocytopenia: 8.2 vs
2.9 (P = 0.016)
• Anemia: 9.8 vs 10.3 (P = 0.88)
• CMV: 4.9 vs 5.4 (P = 0.84)
• Viral infection: 18.4 vs
18.2 (P = 1.000)
Late conversion (>3 months after transplantation)
Bilbao et al.
[26]
N = 25 recipients. Retrospective;
mean of 10 ±
9 months
In refractory rejection: initial
dose 0.5 mg/12 hours
(C0→ 5 ng/mL). For CNI-related
adverse events: 0.5 mg once/twice
a day. For malignancy: 0.5 mg/day,
C0 < 3 ng/mL
• Mucositis: 4
All converted to
EVR
• Sepsis (graft-vs-host disease): 4
Casanovas et
al. [27]
N = 35 recipients.
All converted to
EVR
Prospective,
single-arm;
mean of
134 months
Initial dose 0.25 mg/12 hours for
the first 4 days. Target C0 3–5 ng/mL
Anemia, leukopenia, and
thrombocytopenia: 11.4
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Table 1 Everolimus in liver transplantation (Continued)
Castroagudin
et al. [28]
N = 21 recipients
(chronic renal
dysfunction). All
converted to EVR
Prospective,
single-arm;
median of
19.8 months
0.75 mg b.i.d., C0→ 3–8 ng/mL Change in GFR (mL/min/1.73 m2)
1 year after conversion:
+7.65 (P = 0.016 vs baseline)
De Simone
et al. [29]
N = 40 recipients Prospective,
single-arm 12
months
1.5 mg/day (C0→ 3–8 ng/mL) tBPAR: 15 Change in CrCl (mL/min)
1-year post conversion:
4.03±12.6 (-10.6-52.5)
• Oral ulcers/stomatitis: 22.5
• Lower urinary tract infection: 5
• Pruritis and acne:7.5 each
De Simone
et al. [30]
N = 145 recipients Prospective,
randomized;
12 months
Initial dose of 3 mg/day b.i.d on
day 1. After week 2: EVR
C0→ 3–8 ng/mL with concomitant
CNI or C0→ 6–12 ng/mL if CNI
was eliminated
EVR vs CNI: 4.2 vs 1.4 Change in CrCl (mL/min)
6 months post-conversion:
EVR: +1.0; controls: +2.3 (NS)
EVR vs CNI
• Mouth ulcers: 26.4 vs 0.0
(P < 0.01)
• n = 72 (EVR
therapy with
CNI reduction or
discontinuation) • Infections: 31.9 vs 21.9 (15.3 vs
1.4 suspected to be drug-related)
• n = 73 (CNI
continuation) • Rash/dry skin/eczema: 6.9 vs
0.0 (P = 0.028)
• Leukopenia: 12.5 vs 5.5
• Thrombocytopenia: 5.6 vs 1.4
• Anemia: 9.7 vs 4.1
Saliba et al.
[31]
N = 240
maintenance
recipients. All
received EVR
Retrospective;
12 months
Introduced at mean 2.4 mg/day
(Month 1: C0→ 7.3 ng/mL, Month 12
C0→ 8.1 ng/mL) C0→ 8.8 ng/mL
at Month 12 in monotherapy
cohort
BPAR: 1.6 Change in GFR mL/min/1.73 m2;
(CG method) 1 year after
conversion (overall vs baseline):
+4.2 (P = 0.007) chronic renal
failure (subpopulation vs
baseline): +8.6 (P = 0.02)
• Edema: 16.3
• Stomatitis/mouth ulcers: 14.2
• Bacterial infection:12.5
• Rash: 18.8
• Anemia: 12.9
• Leukopenia: 9.2
• Thrombocytopenia: 6.3
Vallin et al.
[32]
N = 94 recipients. Retrospective;
mean 12 ±
7 months
Initial dose of 0.75–1.5 mg
b.i.d. C0 adjusted to 3–8 ng/mL
9 • Edema: 7
All received EVR • Mucositis: 15
• Infection: 3
• Dermatitis: 19
aBetween-group difference (calculated as CNI group minus everolimus group) at Month 11 after baseline; results based on analysis of covariance model. bTreatment group differences with an exploratory P value of
≤0.05. P values are included where available. b.i.d., twice daily; BPAR, biopsy-proven acute rejection; C0, trough level; CG, Cockcroft-Gault; CI, confidence interval; CMV, cytomegalovirus; CNI, calcineurin inhibitor; CrCl,
creatinine clearance; CsA, cyclosporine A; eGFR, estimated glomerular filtration rate; EVR, everolimus; GFR, glomerular filtration rate; LS, least square; MDRD, modification of diet in renal disease; NS, nonsignificant; RR,
relative risk; rTAC, reduced tacrolimus; SE, standard error; TAC, tacrolimus; TAC-C, standard tacrolimus; TAC-WD, tacrolimus withdrawal; Tx, transplantation.
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evolution of renal function of everolimus with reduced
tacrolimus in de novo liver transplant recipients. Patients
undergoing a successful liver transplantation enter a
run-in period between 3 and 5 days post-transplantation.
During the run-in period, induction therapy, mycophe-
nolate mofetil, tacrolimus and corticosteroids are initi-
ated at the investigator’s discretion. Between 7 and
21 days post-transplantation, patients are randomized in a
1:1 ratio to receive either: (i) everolimus (trough level (C0)
3–8 ng/mL) with reduced tacrolimus (C0 <5 ng/mL), or (ii)
standard tacrolimus (C0 6–10 ng/mL; Figure 1). Everolimus
is initiated on the day of randomization and will be moni-
tored throughout the study period (post 5 ± 2 days of
everolimus/tacrolimus dose changes).
Study population
This study plans to enroll approximately 330 de novo
liver transplant recipients, 165 in each study arm, from
15 transplant centers in Germany. The study population
comprises adult patients aged between 18 and 65 years
receiving a liver transplant from a deceased or living
donor. At the time of randomization, only patients
with an acceptable renal function defined as estimated
glomerular filtration rate (eGFR) >30 mL/min/1.73 m2
assessed by the Modification of Diet in Renal Disease
(MDRD)-4 formula [33] (obtained within 5 days before
randomization) are eligible to enter the study. Inclusion
and exclusion criteria at the time of study entry and
randomization are summarized in Table 2. The study was
approved by all competent Ethics Committees and regu-
latory authorities (Additional files 1 and 2). Informed
consent is being obtained from all patients enrolled to
the study by the investigators.
Study objectives
This study is designed to evaluate the renal function, ef-
ficacy and safety of everolimus with reduced tacrolimus
in liver transplant recipients. The primary objective of
the study is to demonstrate superior eGFR (MDRD-4Figure 1 Study design. *As per center practice. C0, trough levels; CS, cort
transplantation; M, month; MELD, model of end-stage liver disease; MMF, mformula) with the everolimus plus reduced tacrolimus
regimen compared with standard tacrolimus at Month
12. The key secondary objective is to evaluate the inci-
dence of treated biopsy-proven acute rejection, graft
loss, or death at Month 12. Other secondary objectives
are to evaluate: (i) incidences of components of the com-
posite efficacy endpoint; (ii) renal function by eGFR
using various formulae (MDRD-4, Nankivell, Cockcroft-
Gault, chronic kidney disease epidemiology collaboration
and Hoek formulae); (iii) incidence of proteinuria; (iv)
incidence of adverse events and serious adverse events;
and (v) incidence and severity of CMV and HCV infec-
tions and HCV-related fibrosis. Efficacy and safety objec-
tives of the study are summarized in Table 3. All adverse
events and serious adverse events occurring after admin-
istration of study treatment will be documented in case
report forms and patient medical records for further
monitoring.
Randomization and immunosuppression
De novo liver transplant recipients are randomized 7–
21 days post-transplantation to receive everolimus plus
reduced tacrolimus or standard tacrolimus. All eligible
patients are randomized using a validated system that
automates the random assignment of treatment arms in
the specified ratio. Randomization is stratified by HCV
status (positive/negative) and the laboratory MELD score
below/equal/above 30 at transplantation.
Immunosuppression up to the point of randomization
comprises induction therapy, mycophenolate mofetil, ta-
crolimus, and corticosteroids administered according to
local practice. Mycophenolic acid is discontinued at the
time of randomization as per local practice. Patients in
the everolimus plus reduced tacrolimus group are ad-
ministered everolimus on the day of randomization at a
dose of 1.0 mg b.i.d The target therapeutic range for
everolimus is maintained at 3–8 ng/mL and dose adjust-
ments will be monitored 5 ± 2 days post-randomization.
Tacrolimus dose is adjusted to achieve a C0 <5 ng/mL after
everolimus C0 is achieved. In the standard tacrolimusicosteroids; EVR, everolimus; HCV, hepatitis C virus; LTx, liver
ycophenolate mofetil; RND, randomization; TAC, tacrolimus.
Table 2 Key inclusion and exclusion criteria for the Hephaistos study
Inclusion criteria Exclusion criteria
1. Patients able to give written informed consent to
participate in the study
1. Recipients of multiple solid organ transplants
2. Male or female recipients 18–65 years with full-size
liver allograft
2. Patients with renal failure or CKD/ESRD requiring renal replacement therapy
for more than 2 weeks prior to transplantation
3. Negative pregnancy test (females of child bearing age) 3. History of malignancy within the past 5 years
4. HCC that does not fulfill the Milan criteria at the time of transplantation
5. Patients with a known hypersensitivity to the drugs used in the study or
their class, or to any of the excipients
6. Recipients of ABO incompatible transplant grafts
7. HIV positive patients
8. Patients with a current systemic infection or sepsis requiring active
use of intravenous antibiotics
At randomization (Day 7–21 post-liver transplantation)
1. eGFR (MDRD4 formula) >30 mL/min/1.73 m2 1. Platelet count <50,000/mm3, absolute neutrophil count <1,000/mm3, or
a white blood cell count <2,000/mm3
2. Absence of thrombosis prior to any initiation of
treatment with everolimus
2. Hemoglobin <8.0 g/dL
3. Functioning allograft (total bilirubin levels ≤3 times
ULN, and AP, AST, and ALT levels ≤5 times ULN)
3. Uncontrolled hypercholesterolemia or hypertriglyceridemia
4. Proteinuria >1 g/24 hours
5. Patients with infections requiring active use of intravenous antibiotics
ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate;
ESRD, end-stage renal disease; HCC, hepatocellular carcinoma; MDRD4, Modification of Diet in Renal Disease-4; ULN, upper limit of normal.
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both the groups receive corticosteroids at the investigator’s
discretion. The treatment regimens will be continued until
Month 12 post-randomization. Dose adjustments and in-
terruptions are allowed only in patients who are unable to
tolerate the protocol-specified dosing scheme. Everolimus
dose will be: (i) interrupted in severe hematological adverse
events until the condition is resolved; and (ii) permanently
discontinued if a hemolytic uremic syndrome occurs. Ta-
crolimus dose will be adjusted if the whole blood levels are
outside the target range and reduced in case of tacrolimus
toxicity. Follow-up medical care is provided to all patients
who prematurely discontinue from the study as per center
practice.
Rejection episodes are treated as per local practice or
at the investigator’s discretion. Other concomitant medi-
cations such as prophylactic treatment of CMV with val-
ganciclovir, ganciclovir, CMV hyperimmune globulin,
acyclovir or valacyclovir; Pneumocystis carinii with Bac-
trim® or equivalent (trimethoprim/sulfamethoxazole),
oral candida with nystatin suspension and treatment of
hepatitis B and C virus prophylaxis are permitted as per
local practice.
Statistical analysis
This study tests the null hypothesis that there is zero treat-
ment difference in the mean eGFR between the everolimus
plus reduced tacrolimus and standard tacrolimus groups atMonth 12 after baseline. The null hypothesis is tested with
analysis of covariance with treatment, center, HCV class
(positive/negative), and MELD (≤30 vs >30) as factors, and
eGFR at Visit 1 (baseline) as a covariate. An alternative hy-
pothesis assumes that the difference between the two arms
is 7.0 mL/min/1.73 m2. A sample size of 105 in each group
will have 80% power to detect a difference of 7.0 mL/min/
1.73 m2 in the mean eGFR, assuming that the common
standard deviation is 18.0 mL/min/1.73 m2 with a 5% two-
sided significance level. Summary statistics of demographic
and baseline characteristics, efficacy observations and mea-
surements, safety observations and measurements, and
pharmacokinetic measurements will be presented by treat-
ment group. Categorical variables will be summarized by
absolute and relative frequencies, and continuous variables
will be summarized by descriptive statistics. Time-to-event
data including rates of affected patients will be assessed by
Kaplan-Meier statistics. Group comparisons will be per-
formed using appropriate two-sided statistical tests. Physio-
logical, laboratory and clinical assessments will be carried
out as per plan (Additional file 3). Full analysis set will be
used for the analysis of data.
Study conduct, analysis of study outcomes and documen-
tation of the study results will be in accordance with the
Declaration of Helsinki [34], Good Clinical Practice [35],
and the local legal and regulatory requirements. Trial cen-
ters will be randomly audited by funding authorities. All
data management activities will be carried out by a data
Table 3 Objectives of the Hephaistos study
Primary objective To demonstrate that an immunosuppressive regimen based on everolimus with reduced tacrolimus
has superior efficacy compared with tacrolimus alone on eGFR (MDRD-4 formula) at Month 12 in
de novo liver transplant recipients
Key secondary objective To evaluate the incidence of a composite of tBPAR, graft loss, or death at Month 12
Other key secondary efficacy objectives • Incidence of individual and composite efficacy components (tBPAR, graft loss, death, or loss to
follow-up) at Months 6 and 12
• To evaluate treated BPAR by: (1) incidence, (2) time to event, (3) severity, and (4) diagnosis
leading to transplantation
• To evaluate any acute rejection by: (1) incidence, (2) time to event, and (3) severity
Other key renal function-related objectives • Evolution of renal function (eGFR; MDRD-4) over time
• Renal function (eGFR by MDRD-4, Nankivell, Cockcroft-Gault, CKD-EPI, and Hoek formulae)
• To evaluate serum creatinine at various time points
• To evaluate renal function and change in eGFR from screening, randomization, and Week 2
post-transplantation to Months 6 and 12 in various subgroups
• To evaluate urinary protein/creatinine ratio and incidence of proteinuria at various time points
Other key safety-related objectives • Incidence of adverse events/infections/serious adverse events
• Incidence of treatment-related side effects, such as NODM, evolution of metabolic parameters
as subdivisions of serum/plasma lipid panel, neurotoxicity, and hypertension
• Incidence and reason for premature discontinuation of study medication and premature
discontinuation from the study
Key virus (HCV and CMV)- and HCC-related
objectives
• Incidence and rate of progression of HCV, HCV-related fibrosis, and HCV viral load
• Incidence of and response to HCV antiviral treatment
• Incidence of de novo HCC malignancies and rate of recurrence at Month 12
• Incidence and severity of CMV viral infections
BPAR, biopsy-proven acute rejection; CKD-EPI, chronic kidney disease epidemiology collaboration; CMV, cytomegalovirus; eGFR, estimated glomerular filtration
rate; EVR, everolimus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; MDRD, modification of diet in renal disease; NODM, new onset diabetes mellitus;
rTAC, reduced tacrolimus; tBPAR, treated biopsy proven acute rejection.
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operating procedures of Novartis Pharma GmbH, Nürn-
berg, Germany. The data monitoring committee has the
right and duty to recommend study closure if necessary.
Sub-studies
The Hephaistos study will also include five sub-studies
to evaluate:
1. Importance of non-human leukocyte antigen (HLA)
antibodies targeting G-protein coupled receptor in
liver transplant pathologies. This sub-study will
determine: (i) the anti-AT1-receptor and anti-ETA-
receptor antibodies status; (ii) correlation with
immunologic and non-immunologic events; (iii)
the correlation with histopathologic findings, if a
biopsy is available; and (iv) functional outcome.
2. Cytochrome P450 (CYP450)-dependent vasoactive
eicosanoids in serum and urine as a marker and
mediator of nephrotoxicity after liver transplantation.
This sub-study will determine: (i) CYP450-eicosanoid
profile in plasma and urine and correlation with kidney
and liver function as well as histopathologic findings if
a biopsy is available; and (ii) genetic polymorphisms inCYP-isoforms (CYP3A4 and CYP3A5), drug trans-
porters (ABCB1), and catechol-o-methyltransferase in
donor and recipient, and correlation with renal and
liver transplant outcomes.
3. Immunomodulatory effect of everolimus on natural
killer cell subsets and plasma cytokine, chemokine
and growth factor levels in patients after liver
transplantation. The objectives of this sub-study are:
(i) to determine alterations in the major natural
killer cell subsets defined by CD56, CD16, and CD6
surface expression as well as in CD56 and CD6
expression on CD4+ or CD8+ T cells, respectively,
in whole blood of patients before and after liver
transplantation; (ii) to determine the individual course
of the Th1, Th2, and Th17 response in combination
with the chemokine and growth factor response in
the plasma of liver transplant recipients; and (iii) to
determine the correlation of these immune markers
with the type of immunosuppression in both the
treatment groups and with the clinical course after
transplantation (rejection episodes).
4. Impact of everolimus on the development of
alloimmunity and tolerance. The objectives of this
sub-study are: (i) to determine the de novo HLA
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humoral rejection (for example, biliary alteration);
(ii) to determine the changes in the T-cell activation
marker sCD30, tolerance marker HLA-G, and
regulatory antibody IgA-anti-Fab; and (iii) to determine
the changes in regulatory T- and B-cell populations
under everolimus and CNI minimization during the
first year after transplantation. In addition, the study
team plans to investigate the association between the
immunological changes observed during the first year
and outcome during the first 2 years after
transplantation.
5. Immunomodulatory effect of everolimus on
regulatory and innate lymphocyte populations and
on CMV-specific T-cell immunity. The objective of
this sub-study is to test if the immunosuppressive
drug regimen differentially affects individual
immunocompetence towards CMV, CMV-specific
T-cell frequencies, phenotype, and functionality.
The regulatory T-cells will be analyzed in parallel
with CMV load analyses.
Blood samples will be drawn at screening, baseline, and
Days 90 and 360 for the sub-studies and processed to ob-
tain serum and/or plasma. For evaluating the genetic poly-
morphisms, blood samples from recipients and donors are
collected in EDTA at screening. Liver biopsy is preserved if
donor blood is not available. The protocol was amended in
June 2013 to incorporate the details of the sub-studies.
Discussion
This study aims to demonstrate superior renal function,
comparable efficacy, and safety in patients receiving
everolimus plus reduced tacrolimus versus the standard
tacrolimus regimens. This study also evaluates the anti-
viral benefit by initiation of everolimus as early as Day 7.
This study allows very low initial immunosuppression
because of a relevant number of high-MELD patients in
Germany with a poor initial condition.
Trial status
Hephaistos is an ongoing study recruiting de novo liver
transplant recipients at 15 centers across Germany. Cur-
rently 359 patients are screened and, of these, 156 pa-
tients are randomized (78 in each arm). At baseline,
demographic characteristics such as mean age (54.04
versus 54.21 years), male patients (77.8% versus 62.5%),
Caucasian patients (100% versus 95.8%) and mean body
mass index (26.01 versus 26.81 kg/m2) were similar in
the everolimus with reduced tacrolimus and standard ta-
crolimus regimens, respectively. All investigators are in-
volved in final data interpretation and analysis. All trial
results will be disclosed to the health authorities with
subsequent publication in NIM and journals.List of study sites
Universitaetsklinikum Hamburg-Eppendorf Hepatobiliare
Chirurgie; Medizinische Hochschule Hannover; Charite
Berlin Campus Virchow-Klinikum Allg.-,Visceral-,Transpl.-
Chir; Universitatsklinikum Regensburg Chirurgie; Klini-
kum der Universitaet Heidelberg; Universitaetsklinikum
Schleswig-Holstein Campus Kiel Allgemein- und Thorax-
chirurgie; Universitatsklinikum Leipzig AoR Chirurgische
Klinik II; Klinikum der Johannes-Gutenberg Universitaet;
Universitatsklinikum Essen gGmbH Lebertransplantation-
sambulanz; Klinikum Grosshadern Muenchen Chirur-
gische Klinik Poliklinik; Universitaetsklinikum Frankfurt
Chirurgie; Universitatsklinikum Tubingen Chirurgie; Uni-
versitatsklinikum Aachen Allgemein, Viszeral, Transpl.;
Universitatsklinikum Erlangen Chirurgische Klinik; Uni-
versitatsklinikum Bonn Allg./Viszeral/Thorax/Gefass.
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